Literature DB >> 1583878

Gonadal mosaicism in a family with adrenoleukodystrophy: molecular diagnosis of carrier status among daughters of a gonadal mosaic when direct detection of the mutation is not possible.

G E Graham1, P M MacLeod, D P Lillicrap, P J Bridge.   

Abstract

Adrenoleukodystrophy is a severe, X-linked neurological disease that has been shown to be linked to DNA markers from Xq28. We tested several families with these markers and, in one family, found two apparent recombination events between DXS52 and the disease. Expansion of the study to include other tests and several others markers from Xq28 led us to conclude that recombination probably had not occurred and that, instead, the mutation in this family had a mitotic origin and that the grandmother was a gonadal mosaic. For genes that have been cloned, it is often possible to demonstrate the presence or absence of a specific mutation in such families and to determine carrier status on that basis. This is not possible when the gene has not been cloned. We therefore describe a method that can be employed by a molecular diagnostic laboratory to discriminate between people who inherit the same RFLP haplotype, with or without the mutation, from a parent with gonadal mosaicism in diseases where direct gene analysis is not yet possible.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583878     DOI: 10.1007/bf01800346

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

1.  Molecular analysis of hemophilia A mutations in the Finnish population.

Authors:  B Levinson; A E Lehesjoki; A de la Chapelle; J Gitschier
Journal:  Am J Hum Genet       Date:  1990-01       Impact factor: 11.025

Review 2.  Review and hypotheses: somatic mosaicism: observations related to clinical genetics.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

3.  Mosaicism for an intragenic deletion in a boy with mild ornithine transcarbamylase deficiency.

Authors:  A Maddalena; D M Sosnoski; G T Berry; R L Nussbaum
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

4.  Report of the committee on the genetic constitution of the X and Y chromosomes.

Authors:  K E Davies; J L Mandel; J Weissenbach; M Fellous
Journal:  Cytogenet Cell Genet       Date:  1987

5.  Maternal duplication associated with gene deletion in sporadic hemophilia.

Authors:  J Gitschier
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

6.  Molecular diagnosis of the fragile X [Fra (X)] syndrome: calculation of risks based on flanking DNA markers in small phase-unknown families.

Authors:  P J Bridge; D P Lillicrap
Journal:  Am J Med Genet       Date:  1989-05

7.  Linkage of adrenoleukodystrophy to a polymorphic DNA probe.

Authors:  P R Aubourg; G H Sack; D A Meyers; J J Lease; H W Moser
Journal:  Ann Neurol       Date:  1987-04       Impact factor: 10.422

8.  Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Authors:  H W Moser; A E Moser; I Singh; B P O'Neill
Journal:  Ann Neurol       Date:  1984-12       Impact factor: 10.422

9.  Familial adrenoleukodystrophy: long chain fatty acid levels and analysis with a factor VIII DNA probe.

Authors:  S Berriche; J C Turpin; G Lucotte
Journal:  J Neurol       Date:  1988-03       Impact factor: 4.849

10.  Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.

Authors:  H W Moser; A B Moser; K K Frayer; W Chen; J D Schulman; B P O'Neill; Y Kishimoto
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

View more
  2 in total

1.  Is skewed X inactivation responsible for symptoms in female carriers for adrenoleucodystrophy?

Authors:  E Watkiss; T Webb; S Bundey
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

Review 2.  DNA diagnosis of X-linked adrenoleukodystrophy.

Authors:  S Seneca; W Lissens
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.